Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept and Cytokine Levels in DME Patients
NCT02645266Active, not recruiting
- Sponsor
- McMaster University
- Start
- May 2018
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by McMaster University. Primary endpoint: Best Corrected Visual Acuity at 5 months. Started May 2018; status: active, not recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02645266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02645266.